Clinical trials: Endometrial Cancer, open to volunteers
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
- Trial name
- NCT05950464
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
This phase II trial studies whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response (absence of cancer cells in tissue samples after treatment) in women with…
- Trial name
- NCT07349641
- Testing
- Medical Device Usage and Evaluation, Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
The Use of a Novel Vaginal Speculum for Endometrial Biopsies
The objective of this clinical trial is to determine if a newly-designed and FDA-cleared vaginal speculum (the Bouquet Speculum) will provide better visualization of the cervical os, be easier and more efficient to use, provide…
- Trial name
- NCT07217353
- Testing
- Bouquet Speculum
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Rocky Vista University, LLC
Endometrial Cancer
Tirzepatide in the Treatment of Endometrial Cancer
This study is looking for a better way to treat pre-cancer or early-stage cancer in the lining of the uterus in women who are also overweight.
- Trial name
- TREAT-EC (NCT07605247)
- Testing
- Tirzepatide, LNG-IUD plus tirzepatide
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II…
- Conditions
- Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT06855706
- Testing
- Behavioral Intervention, Best Practice, Biospecimen Collection
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer, Colon Cancer
Cancer Loyalty Card Study 2 (CLOCS-2)
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early.
- Conditions
- Pancreatic Cancer, Colon Cancer, Oesophageal Cancer, Stomach Cancer
- Trial name
- (CLOCS-2) (NCT06447064)
- Testing
- Cases & Controls
- Where
- United Kingdom
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Imperial College London
MMRd/MSI-H Stage II-III Endometrial Cancer
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer.
- Trial name
- NADIA (NCT07013851)
- Testing
- Dostarlimab
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
HER2-Expressing Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors.
- Trial name
- NCT07334119
- Testing
- MT-304, MT-304 + Nivolumab
- Where
- 7 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Myeloid Therapeutics
Endometrial Cancer
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied
- Trial name
- NCT05819892
- Testing
- Paclitaxel, Carboplatin, Dostarlimab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Endometrial Cancer
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
- Trial name
- NCT06276491
- Testing
- XmAb541
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 282 people
- Sponsor
- Xencor, Inc.
Endometrial Cancer
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent…
- Trial name
- EndoMAP (NCT04486352)
- Testing
- Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib
- Where
- 21 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alliance Foundation Trials, LLC.
Brachytherapy, Uterine Cervical Neoplasms
Retrospective Study of Brachytherapy
Brachytherapy for gynecological cancers will be studied retrospectively.
- Conditions
- Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer
- Trial name
- RetroBT (NCT05242861)
- Testing
- Brachytherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Endometrial Cancer, Endometrial Intraepithelial Neoplasia
A Multi-center Prospective Study on the Oncological and Reproductive Outcomes and Quality of Life in Young Woman After Fertility-sparing Treatment of Endometrial Cancer and Endometrial Intraepithelial Hyperplasia
We will investigate the safety and efficiency of fertility-sapring treatment in ypung women witg endometrial cancer and endometrial intraepithelial hyperplasia
- Conditions
- Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Fertility-sparing Surgery
- Trial name
- PreFerEC/EIN (NCT06745427)
- Volunteers
- 100 people
- Sponsor
- Region Stockholm
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Ovarian Neoplasms, Endometrial Neoplasms
DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer, Ovarian Cancer
- Trial name
- DOvEEgene (NCT02288676)
- Where
- Canada
- Volunteers
- 1,200 people
- Sponsor
- McGill University
SBRT, Radiation Therapy
Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)
The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer…
- Conditions
- SBRT, Radiation Therapy, Endometrial Cancer, Endometrial Cancer Stage III
- Trial name
- PURE-cohort (NCT07779109)
- Testing
- Ultra-hypofractionation schedule of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT/VMAT radiotherapy
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2…
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian Cancer
- Trial name
- NCT07612891
- Testing
- INV-6452
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Endometrial Cancer
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Patients with advanced mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) endometrial cancer (EC) are currently treated as one entity, and immune checkpoint inhibitor (ICI) monotherapy is the treatment of…
- Trial name
- CAN-RESPOND (NCT05550558)
- Testing
- Anlotinib + Camrelizumab
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.